Improving of psychological status and inflammatory biomarkers during omalizumab for chronic spontaneous urticaria.

Laura Diluvio,Laura Vollono,Caterina Lanna,Barbara Chiaramonte,Arianna Piccolo,Elena Campione,Luca Bianchi,Francesco Marasco,Cinzia Niolu

doi:10.2144/fsoa-2020-0087

Abstract

Background:Depression and anxiety are the most common psychiatric comorbidities in chronic spontaneous urticaria (CSU). Omalizumab is a monoclonal antibody approved for CSU treatment. We evaluated the prevalence of anxiety and depression in CSU patients before and after treatment with omalizumab.Materials & methods:A total of 30 patients were enrolled in the study: 15 patients affected by CSU and treated with omalizumab and the other 15 healthy subjects did not receive any systemic therapy. All patients were evaluated using Hospital Anxiety and Depression Scale, CRP and erythrocyte sedimentation rate, at baseline and after 6 months.Results:The omalizumab group after 6 months of therapy had a decrease of all the scores and biomarkers.Conclusion:Omalizumab allowed an improvement of urticaria and mental comorbidities.

Highlights

Depression and anxiety are the most common psychiatric comorbidities in chronic spontaneous urticaria (CSU)
Our study highlights the importance of investigating and managing mental comorbidities in the treatment of Chronic spontaneous urticaria (CSU), as this may result in a significant improvement of both psychiatric and dermatological symptoms
We would suggest a holistic approach to CSU patients, combining omalizumab with specific treatments for mental disorders

Summary

Introduction

Depression and anxiety are the most common psychiatric comorbidities in chronic spontaneous urticaria (CSU). Omalizumab is a monoclonal antibody approved for CSU treatment. We evaluated the prevalence of anxiety and depression in CSU patients before and after treatment with omalizumab. Materials & methods: A total of 30 patients were enrolled in the study: 15 patients affected by CSU and treated with omalizumab and the other 15 healthy subjects did not receive any systemic therapy. All patients were evaluated using Hospital Anxiety and Depression Scale, CRP and erythrocyte sedimentation rate, at baseline and after 6 months. Results: The omalizumab group after 6 months of therapy had a decrease of all the scores and biomarkers. Conclusion: Omalizumab allowed an improvement of urticaria and mental comorbidities

Objectives

Methods

Results

Discussion

Conclusion